Compare · PRCT vs RMD
PRCT vs RMD
Side-by-side comparison of PROCEPT BioRobotics Corporation (PRCT) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRCT and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.07B, about 32.8x PRCT ($1.04B).
- Over the past year, PRCT is down 46.8% and RMD is down 10.8% - RMD leads by 35.9 points.
- RMD has been more active in the news (9 items in the past 4 weeks vs 6 for PRCT).
- Both have 25 recent analyst ratings on file.
- Company
- PROCEPT BioRobotics Corporation
- ResMed Inc.
- Price
- $17.57-3.17%
- $239.08-1.35%
- Market cap
- $1.04B
- $34.07B
- 1M return
- -9.76%
- +4.60%
- 1Y return
- -46.76%
- -10.84%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 6
- 9
- Recent ratings
- 25
- 25
PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest PRCT
- PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026
- Barclays initiated coverage on PROCEPT BioRobotics with a new price target
- SEC Form 4 filed by PROCEPT BioRobotics Corporation
- SEC Form 3 filed by PROCEPT BioRobotics Corporation
- PROCEPT BioRobotics Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- PROCEPT BioRobotics Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- EVP, CLO, CORP. SEC. Nouri Alaleh sold $6,223 worth of shares (297 units at $20.95), decreasing direct ownership by 0.23% to 127,737 units (SEC Form 4) to cover withholding tax
- EVP, Chief Technology Officer Templin Barry L sold $7,815 worth of shares (373 units at $20.95), decreasing direct ownership by 0.39% to 94,826 units (SEC Form 4) to cover withholding tax
- EVP, CFO Waters Kevin sold $7,815 worth of shares (373 units at $20.95), decreasing direct ownership by 0.21% to 180,355 units (SEC Form 4) to satisfy withholding tax
- PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target